Wells Fargo Initiates Coverage On aTyr Pharma with Overweight Rating, Announces Price Target of $17
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has initiated coverage on aTyr Pharma with an Overweight rating and set a price target of $17.
October 04, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo has initiated coverage on aTyr Pharma with an Overweight rating and a price target of $17, indicating a positive outlook.
The initiation of coverage with an Overweight rating by a major financial institution like Wells Fargo is a strong positive signal for aTyr Pharma. The $17 price target suggests potential upside from current levels, likely leading to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100